Health Care·Biotechnology·$3.7B
Twist Bioscience Corporation (TWST) operates in the biotechnology sector, focusing on DNA synthesis and gene editing technologies. Its innovative solutions are crucial for advancements in healthcare, agriculture, and industrial applications, making it a key player in the growing biotech industry.
EPS
Earnings per share (EPS) is a critical measure of profitability, and this quarter's consensus reflects ongoing challenges in achieving profitability.
Revenue
Revenue growth is essential for assessing the company's market traction and demand for its products, especially in a competitive biotech landscape.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
+9.97%
Avg Stock Reaction
-2.59%
In Q1-2026, Twist reported an EPS of $-0.50, which was a larger loss than analysts expected. The stock reacted positively, gaining nearly 14% the following day, indicating some investor optimism despite the loss.
Management Promises & Guidance
Analysts expect Twist to report a loss of $-0.53 per share on revenues of $108 million. Given the company's recent performance, there is a mix of cautious optimism and skepticism among investors.
Bull Case
If Twist can exceed revenue expectations and show signs of narrowing losses, it could signal a turnaround and attract more investor interest, potentially driving the stock higher.
Bear Case
Conversely, if the company fails to meet revenue expectations or reports a larger loss, it may reinforce concerns about its growth strategy and lead to a significant drop in stock price.
EPS
$-0.53Earnings per share (EPS) is a critical measure of profitability, and this quarter's consensus reflects ongoing challenges in achieving profitability.
Revenue
$108MRevenue growth is essential for assessing the company's market traction and demand for its products, especially in a competitive biotech landscape.
The print will turn on these two things.
Q1
Will Twist Bioscience achieve revenue of at least $108 million this quarter?
Meeting or exceeding this revenue target is critical for demonstrating demand and market traction, which could influence investor sentiment.
Q2
How does management plan to address the ongoing losses reflected in the EPS?
Investors will be keen to hear about strategies for improving profitability, as sustained losses could raise concerns about the company's long-term viability.
Why consensus could be wrong
The Street may be underestimating the potential for Twist to leverage its technology for new revenue streams, which could drive unexpected growth this quarter.
Supporting Evidence
Recent innovations in DNA synthesis could open new markets that analysts have not fully accounted for.
The company's historical ability to surprise on the upside, as seen in Q3-2025, suggests that current estimates may be conservative.
Key Risk
If Twist's revenue exceeds $108 million, it could challenge the current bearish outlook and shift market sentiment.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to balance growth with profitability, making this quarter's results particularly pivotal.
Bull Confirmed If
Achieving revenue growth above $108 million and a smaller EPS loss than expected could confirm a positive outlook.
Bear Confirmed If
Reporting a larger loss than $-0.53 or failing to meet revenue expectations would reinforce bearish sentiment.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment leading up to the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Twist beats expectations, history suggests the stock could rise by around 0.72%, confirming a positive shift in investor sentiment.
In-Line / Cautious
An inline report may lead to a muted reaction, as investors assess management's commentary on future growth prospects.
Miss
If the company misses expectations, history suggests a potential decline of about 5.90%, reflecting ongoing concerns about its financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COLGATE PALMOLIVE CO
May 1, 2026